 Gwendolyn Kerby
Concepts (129)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Cystic Fibrosis | 9 | 2018 | 964 | 0.910 |
Why?
| | Tobacco Smoke Pollution | 6 | 2022 | 233 | 0.860 |
Why?
| | Respiratory Function Tests | 8 | 2015 | 526 | 0.840 |
Why?
| | Smoking Cessation | 4 | 2022 | 360 | 0.580 |
Why?
| | Pseudomonas Infections | 2 | 2018 | 193 | 0.510 |
Why?
| | Spirometry | 4 | 2012 | 263 | 0.480 |
Why?
| | Cough | 3 | 2013 | 102 | 0.440 |
Why?
| | Neuroendocrine Cells | 1 | 2012 | 30 | 0.440 |
Why?
| | Plethysmography | 4 | 2012 | 124 | 0.330 |
Why?
| | Lung | 4 | 2015 | 3664 | 0.330 |
Why?
| | Lung Diseases, Interstitial | 1 | 2012 | 464 | 0.310 |
Why?
| | Cotinine | 3 | 2021 | 76 | 0.280 |
Why?
| | Child, Preschool | 12 | 2022 | 9491 | 0.250 |
Why?
| | Prednisone | 2 | 2019 | 235 | 0.240 |
Why?
| | Sodium Chloride | 2 | 2015 | 144 | 0.230 |
Why?
| | Dexamethasone | 2 | 2019 | 320 | 0.220 |
Why?
| | Forced Expiratory Volume | 4 | 2015 | 520 | 0.210 |
Why?
| | Child, Hospitalized | 2 | 2020 | 43 | 0.210 |
Why?
| | JNK Mitogen-Activated Protein Kinases | 1 | 2002 | 155 | 0.210 |
Why?
| | Oscillometry | 2 | 2011 | 34 | 0.210 |
Why?
| | Electronic Health Records | 2 | 2021 | 829 | 0.200 |
Why?
| | Respiratory Physiological Phenomena | 1 | 2021 | 31 | 0.200 |
Why?
| | Hospitals, Pediatric | 3 | 2019 | 505 | 0.190 |
Why?
| | Information Systems | 1 | 2021 | 66 | 0.190 |
Why?
| | Sample Size | 1 | 2010 | 133 | 0.180 |
Why?
| | Parents | 4 | 2021 | 1212 | 0.180 |
Why?
| | Infant | 11 | 2022 | 8293 | 0.170 |
Why?
| | Azithromycin | 1 | 2018 | 81 | 0.160 |
Why?
| | Clinical Trials as Topic | 2 | 2011 | 969 | 0.140 |
Why?
| | Macrophages | 1 | 2002 | 1324 | 0.130 |
Why?
| | Environmental Exposure | 1 | 2018 | 405 | 0.130 |
Why?
| | Bronchoscopy | 1 | 2016 | 247 | 0.120 |
Why?
| | Pseudomonas aeruginosa | 2 | 2018 | 305 | 0.120 |
Why?
| | Child | 10 | 2022 | 19129 | 0.110 |
Why?
| | Hyperplasia | 1 | 2012 | 170 | 0.110 |
Why?
| | Saline Solution, Hypertonic | 1 | 2012 | 56 | 0.110 |
Why?
| | Feasibility Studies | 2 | 2011 | 749 | 0.100 |
Why?
| | Male | 14 | 2020 | 57801 | 0.100 |
Why?
| | Cross-Sectional Studies | 2 | 2012 | 4552 | 0.100 |
Why?
| | Asthma | 2 | 2019 | 2158 | 0.100 |
Why?
| | Humans | 19 | 2022 | 118972 | 0.100 |
Why?
| | Anti-Bacterial Agents | 2 | 2018 | 1510 | 0.100 |
Why?
| | Colorado | 3 | 2020 | 4196 | 0.100 |
Why?
| | Longitudinal Studies | 3 | 2013 | 2513 | 0.090 |
Why?
| | Patient Readmission | 1 | 2016 | 634 | 0.090 |
Why?
| | Practice Patterns, Physicians' | 1 | 2019 | 1200 | 0.090 |
Why?
| | Smoking Prevention | 2 | 2021 | 150 | 0.090 |
Why?
| | Reproducibility of Results | 3 | 2013 | 2874 | 0.090 |
Why?
| | Sensitivity and Specificity | 2 | 2011 | 1795 | 0.090 |
Why?
| | Female | 12 | 2018 | 61564 | 0.080 |
Why?
| | Smoking | 3 | 2021 | 1487 | 0.080 |
Why?
| | Cystic Fibrosis Transmembrane Conductance Regulator | 1 | 2011 | 288 | 0.080 |
Why?
| | Inpatients | 2 | 2022 | 388 | 0.080 |
Why?
| | Follow-Up Studies | 2 | 2012 | 4596 | 0.070 |
Why?
| | Double-Blind Method | 3 | 2018 | 1687 | 0.060 |
Why?
| | Postoperative Complications | 1 | 2016 | 2235 | 0.060 |
Why?
| | Case-Control Studies | 1 | 2011 | 3171 | 0.060 |
Why?
| | Administration, Inhalation | 2 | 2018 | 656 | 0.060 |
Why?
| | Glucocorticoids | 1 | 2008 | 545 | 0.060 |
Why?
| | Adolescent | 5 | 2022 | 18480 | 0.060 |
Why?
| | MAP Kinase Kinase 4 | 1 | 2002 | 24 | 0.050 |
Why?
| | Chromones | 1 | 2002 | 37 | 0.050 |
Why?
| | Osmotic Pressure | 1 | 2002 | 32 | 0.050 |
Why?
| | Flavonoids | 1 | 2002 | 71 | 0.050 |
Why?
| | Mitogen-Activated Protein Kinase Kinases | 1 | 2002 | 116 | 0.050 |
Why?
| | Mice, Inbred C3H | 1 | 2002 | 250 | 0.050 |
Why?
| | Morpholines | 1 | 2002 | 106 | 0.050 |
Why?
| | Mitogen-Activated Protein Kinase 1 | 1 | 2002 | 173 | 0.050 |
Why?
| | Cohort Studies | 1 | 2011 | 5116 | 0.050 |
Why?
| | Recurrence | 2 | 2018 | 975 | 0.050 |
Why?
| | p38 Mitogen-Activated Protein Kinases | 1 | 2002 | 285 | 0.050 |
Why?
| | Single-Blind Method | 1 | 2021 | 269 | 0.050 |
Why?
| | Mitogen-Activated Protein Kinases | 1 | 2002 | 298 | 0.050 |
Why?
| | MAP Kinase Signaling System | 1 | 2002 | 292 | 0.050 |
Why?
| | Tobacco Use | 1 | 2020 | 58 | 0.050 |
Why?
| | Proto-Oncogene Proteins c-akt | 1 | 2002 | 420 | 0.050 |
Why?
| | Vital Capacity | 1 | 2010 | 260 | 0.040 |
Why?
| | Retrospective Studies | 2 | 2016 | 12978 | 0.040 |
Why?
| | Pulmonologists | 1 | 2019 | 15 | 0.040 |
Why?
| | Symptom Flare Up | 1 | 2019 | 41 | 0.040 |
Why?
| | Drug Substitution | 1 | 2019 | 46 | 0.040 |
Why?
| | Reference Values | 1 | 2010 | 774 | 0.040 |
Why?
| | Cell Survival | 1 | 2002 | 1047 | 0.040 |
Why?
| | Tobramycin | 1 | 2018 | 50 | 0.040 |
Why?
| | Proto-Oncogene Proteins | 1 | 2002 | 618 | 0.040 |
Why?
| | Directive Counseling | 1 | 2018 | 42 | 0.040 |
Why?
| | Enzyme Inhibitors | 1 | 2002 | 827 | 0.040 |
Why?
| | Family | 1 | 2022 | 585 | 0.040 |
Why?
| | Drug Administration Schedule | 1 | 2019 | 736 | 0.040 |
Why?
| | Tumor Necrosis Factor-alpha | 1 | 2002 | 1171 | 0.040 |
Why?
| | Consensus | 1 | 2019 | 534 | 0.040 |
Why?
| | Pneumonia | 1 | 2002 | 592 | 0.040 |
Why?
| | Dimensional Measurement Accuracy | 1 | 2015 | 12 | 0.030 |
Why?
| | Hospitalists | 1 | 2019 | 173 | 0.030 |
Why?
| | Drug Therapy, Combination | 1 | 2018 | 965 | 0.030 |
Why?
| | Treatment Outcome | 3 | 2018 | 9342 | 0.030 |
Why?
| | Caregivers | 1 | 2022 | 709 | 0.030 |
Why?
| | Self Report | 1 | 2019 | 699 | 0.030 |
Why?
| | Social Support | 1 | 2018 | 542 | 0.030 |
Why?
| | Prospective Studies | 3 | 2012 | 6471 | 0.030 |
Why?
| | Cells, Cultured | 1 | 2002 | 4077 | 0.030 |
Why?
| | Adult | 3 | 2020 | 31512 | 0.030 |
Why?
| | Young Adult | 2 | 2020 | 10793 | 0.030 |
Why?
| | Emergency Service, Hospital | 2 | 2019 | 1864 | 0.030 |
Why?
| | Functional Residual Capacity | 1 | 2013 | 7 | 0.030 |
Why?
| | Apoptosis | 1 | 2002 | 2484 | 0.030 |
Why?
| | Isotonic Solutions | 1 | 2012 | 43 | 0.030 |
Why?
| | Radiography, Thoracic | 1 | 2013 | 164 | 0.030 |
Why?
| | Clinical Competence | 1 | 2019 | 951 | 0.030 |
Why?
| | Age Factors | 1 | 2019 | 2995 | 0.030 |
Why?
| | Body Height | 1 | 2012 | 187 | 0.020 |
Why?
| | Severity of Illness Index | 1 | 2019 | 2674 | 0.020 |
Why?
| | United States | 2 | 2021 | 12555 | 0.020 |
Why?
| | Infant, Newborn | 1 | 2022 | 5255 | 0.020 |
Why?
| | Hospitalization | 1 | 2019 | 1785 | 0.020 |
Why?
| | Staphylococcus aureus | 1 | 2013 | 394 | 0.020 |
Why?
| | Middle Aged | 2 | 2018 | 27617 | 0.020 |
Why?
| | Aged, 80 and over | 1 | 2010 | 6561 | 0.020 |
Why?
| | Staphylococcal Infections | 1 | 2013 | 346 | 0.020 |
Why?
| | Quality Improvement | 1 | 2016 | 963 | 0.020 |
Why?
| | Time Factors | 1 | 2018 | 6412 | 0.020 |
Why?
| | Body Weight | 1 | 2012 | 934 | 0.020 |
Why?
| | Statistics, Nonparametric | 1 | 2008 | 403 | 0.020 |
Why?
| | Chi-Square Distribution | 1 | 2008 | 525 | 0.020 |
Why?
| | Administration, Oral | 1 | 2008 | 756 | 0.020 |
Why?
| | Mice | 1 | 2002 | 15520 | 0.020 |
Why?
| | Risk Factors | 1 | 2016 | 9000 | 0.010 |
Why?
| | Aged | 1 | 2010 | 19657 | 0.010 |
Why?
| | Animals | 1 | 2002 | 33381 | 0.010 |
Why?
|
|
Kerby's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|